Your session is about to expire
← Back to Search
Ketamine for Major Depressive Disorder
Study Summary
This trial will help determine if the levels of GABA and glutamate in the brain are associated with remission from depression after ketamine treatment.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received ketamine treatment for depression in the last 2 months.You have a condition called gastroesophageal reflux disease (GERD), which affects your stomach and esophagus.You have been diagnosed with Complex Regional Pain Syndrome (CRPS).You have a fear of enclosed spaces (claustrophobia).You have experienced a head injury that made you lose consciousness.You have a condition that affects your learning or thinking abilities.Your main diagnosis is a personality disorder.You have been diagnosed with schizophrenia, schizoaffective disorder, post-traumatic stress disorder, or currently experiencing severe symptoms of psychosis.You are currently receiving treatments like TMS, vagal nerve stimulation, or deep brain stimulation for depression.You have been diagnosed with confusion or brain-related problems in the past year.You have tried using ketamine in the past to treat your depression symptoms, but it did not work well or you had trouble tolerating it.You cannot take certain medications that affect the brain chemicals glutamate or GABA for two weeks before starting the study.You have a history of substance abuse, but you can still participate if you have been completely free from substance use for more than a year.You have had electroconvulsive therapy (ECT) in the past year.You have a problem with your memory or thinking abilities, as diagnosed by a doctor.You have a mental health condition other than anxiety that requires treatment with antidepressant medication.
- Group 1: Ketamine
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of participants in this experiment?
"This experiment is no longer accepting volunteers. The listing was initially posted on March 1st, 2019 and the last update occurred on September 12th, 2022. If you are seeking alternative trials, there currently exist 1393 studies with psychosis as their primary focus plus 105 investigations studying this particular treatment that remain open for enrollment."
Would I be a suitable candidate for participating in this research program?
"This trial seeks 20 individuals aged between 18 and 65, with a diagnosis of involutional psychosis. In order to be eligible for the study, participants must provide informed consent, receive psychiatric treatment as either an inpatient or outpatient, score at least 15 on the PHQ-9 scale during screening and baseline assessments; have experienced failure in two prior antidepressant treatments (including pharmacotherapy over 8 weeks or 6 administrations of ECT/TMS); and pass an assessment test related to ketamine's effects."
Is this clinical trial open to individuals senior in age?
"This medical experiment is open to candidates aged 18 or above and below 65."
Is recruitment for the clinical trial still ongoing?
"At the moment, this medical trial is not recruiting. First posted on March 1st 2019 and last updated September 12th 2022, it has since been suspended. For those looking for other studies that are actively accepting patients, 1393 trials related to psychosis and involutional therapies are currently enrolling participants."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger